Imaging insulin-making cells in adults with type 1 diabetes
Uses a PET scan to measure insulin-producing cells in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Image-Verapamil SR in Adults with Type 1 Diabetes (Image-VER-A-T1D)
Key facts
- Where
- Graz and Vienna, AustriaSee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who are already in the VER-A-T1D trial and have not started treatment or placebo yet.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- People must not have started treatment or placebo in the VER-A-T1D trial. They must not take synthetic exendin (Exentide, Byetta®) or dipeptidyl-peptidase IV inhibitors.
Main reasons for not taking part
- Treatment with synthetic exendin (Exentide, Byetta®) or dipeptidyl-peptidase IV inhibitors
- Kidney disease (MDRD < 40 ml/min/1.73m²)
- Pregnancy, or the wish to become pregnant within 2 months after the second PET/CT scan
Read by machine on 9 November 2026.
Where in Austria
- University Hospital GrazGraz, AustriaNot yet recruiting
- Medical University of ViennaVienna, AustriaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Radboud universitair medisch centrum Stichting
- Trial code
- NCT04615910EU 2024-518554-17-00
- Record updated
- 14 April 2025
- Original description
To measure pancreatic uptake of 68Ga-NODAGA-exendin by PET/CT for detection of intra-individual differences in beta cell mass before and after treatment and inter-individual differences between the treatment group and the placebo group.Read full original descriptionShow less
A GLP-1 receptor PET imaging add-on study within the VERA-T1D trial investigating the effects on beta cell mass (Image-VER-A-T1D)
To measure pancreatic uptake of 68Ga-NODAGA-exendin by PET/CT for detection of intra-individual differences in beta cell mass before and after treatment and inter-individual differences between the treatment group and the placebo group.
Inclusion: Are included in the VER-A-T1D trial, but have not started treatment/placebo; have given written informed consent; Age ≥18 years at consent.
Exclusion: Treatment with synthetic exendin (Exentide, Byetta®) or dipeptidyl-peptidase IV inhibitors (to exclude interferences with imaging), specifically mentioned although in principle part of exclusion criteria VER-A-T1D; Renal disease defined as MDRD < 40 ml/min/1.73m²; Pregnancy or the wish to become pregnant within 2 months after second PET/CT scan.